Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now

DOI: 10.1128/CVI.00089-15

Article Figures & Data

TABLE 1

Rationale for vaccine development for nontypeable Haemophilus influenzae

Infection	Population to vaccinate	What vaccine will accomplish
Otitis media	All children beginning at 2 mo of age	Prevention of:
		Acute otitis media
		Recurrent otitis media
		Chronic otitis media
		Otitis media with effusion related to bacterial biofilm formation
		Chronic suppurative otitis media
		Reductions in:
		Excess antibiotic use
		Health care costs
Exacerbation of COPD	Adults with COPD	Prevention of:
		Acute exacerbations of COPD
		Chronic airway colonization
		Reductions in:
		Excess antibiotic use
		Health care costs

TABLE 2

Haemophilus influenzae vaccine antigens under study

Antigen	Molecular mass (kDa)	Function	Reference(s)
Haemophilus adhesin protein (Hap)	∼155	Adhesin	71–73
HMW1, HMW2	120–125	Adhesins	74–76
H. influenzae adhesin (Hia)	∼115	Adhesin	77, 78
D15 protein	∼80	Predicted nucleotidyltransferase	79, 80
HtrA	∼46	Heat shock protein	81
P2 porin	36–42	Porin protein	65, 66, 82
Lipoprotein D	∼42	Glycerophosphodiester phosphodiesterase	45, 56, 83
P5 fimbrin	27–35	Adhesin, OMP A-like protein	51, 84–86
P4 protein	∼30	Acid phosphatase	87–89
Protein F	∼30	Adhesin, ABC transporter	90–92
OMP 26	∼26	Skp family of translocation proteins	85, 93–95
P6 protein	∼16	Peptidoglycan-associated lipoprotein	96–102
Protein E	∼16	Adhesin, binds IgD	103–106
PilA (type IV pilus)	∼14	Adhesin, transformation	51, 107–109
Detoxified lipooligosaccharide	3–5	Endotoxin	110–113